Losartan Potassium and Hydrochlorothiazide tablets recalled for AZIDO impurity
Lupin Pharmaceuticals recalls Losartan Potassium and Hydrochlorothiazide tablets nationwide due to manufacturing deviations that resulted in AZIDO impurity levels above acceptable limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with confirmed manufacturing deviation (CGMP violation) resulting in AZIDO chemical impurity exceeding acceptable limits. This represents a risk-of-harm pharmaceutical product where injury has not yet been reported, fitting the rubric criterion for score 3.
Plain-English summary
Lupin Pharmaceuticals Inc. is recalling specific lots of Losartan Potassium and Hydrochlorothiazide Tablets USP (100 mg/12.5 mg) distributed nationwide. The recall affects 2,361,924 bottles in both 30-count (NDC 68180-216-06) and 90-count (NDC 68180-216-09) configurations.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations in which AZIDO impurity levels were observed to be above acceptable limits. This manufacturing defect was identified at the Lupin Limited facility in Pithampur, India, which manufactures the product for Lupin Pharmaceuticals Inc. in Baltimore, Maryland.
Affected lot numbers for 30-count bottles include H001878, H002178, H002626, and H102149. Numerous 90-count bottle lots from H001600 through H102271 are also affected, with expiration dates ranging from May 2022 through September 2023.
Patients currently taking this medication should contact their healthcare provider before discontinuing use. Consumers should return any affected product to their pharmacy or the manufacturer.
The recalled product
- Product
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)
- Brand
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Affected units
- 2,361,924
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
UPCs (2)
- 0368180215066
- 0368180217060
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 6 recalled by Lupin Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 6 products in this recall →Related recalls
Same brand · LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- HighLosartan Potassium and Hydrochlorothiazide Tablets Recalled for Foreign Plastic Contamination
FDA (Drugs) · 2024-05-22
- HighFDA Recalls Losartan-Hydrochlorothiazide Tablets for Manufacturing Quality Deviations
FDA (Drugs) · 2022-07-06
- HighBlood Pressure Medication Losartan-HCTZ Recalled for Impurity Deviation
FDA (Drugs) · 2022-06-08
- HighBlood pressure medication Losartan and hydrochlorothiazide recalled for elevated azido impurity
FDA (Drugs) · 2022-06-01
- HighLosartan Potassium and Hydrochlorothiazide Recall: Impurity Levels Above Acceptable Limits
FDA (Drugs) · 2022-06-01
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateGanirelix acetate injection recalled after failing an impurity specification
FDA (Drugs) · 2025-12-17
Same hazard · azido impurity
See all →- HighLosartan Potassium Tablets Recalled for Elevated AZIDO Impurity Levels
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium tablets recalled for elevated AZIDO impurity
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for Manufacturing Impurity Issues
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for CGMP Deviations and Elevated Impurity
FDA (Drugs) · 2022-06-08